Delta-Fly Pharma (TYO:4598) said it will begin a phase 2/3 trial for DFP-17729 combined with TS-1 in patients with advanced pancreatic cancer after receiving approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), according to a Monday filing on the Tokyo Stock Exchange.
The study, to be conducted at 15 clinical sites in Japan, will measure overall survival as the primary endpoint. If DFP-17729 with TS-1 shows superior efficacy to TS-1 alone, the drug could receive new drug approval from the PMDA.
TS-1, developed by Taiho Pharmaceutical, is used to treat several cancers, including pancreatic cancer.
Price (JPY): $590.00, Change: $+9.0, Percent Change: +1.55%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.